Androgen receptor in triple negative breast cancer

Journal of Steroid Biochemistry and Molecular Biology

Volumn 133, Issue 1, 2013, Pages 66-76

  McNamara, K M ^a   Yoda, T ^a   Takagi, K ^b   Miki, Y ^a   Suzuki, T ^b   Sasano, H ^a,b  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Androgen receptor; Steroid metabolism; TNBC

Indexed keywords

ANDROGEN RECEPTOR; BICALUTAMIDE; BRCA1 PROTEIN; BRCA2 PROTEIN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ANDROGEN METABOLISM; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CELL PROLIFERATION; GENETIC TRANSFECTION; HISTOPATHOLOGY; HUMAN; INTRACELLULAR SIGNALING; INTRADUCTAL CARCINOMA; PREDICTIVE VALUE; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TRIPLE NEGATIVE BREAST CANCER;

ANDROGEN ANTAGONISTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; FEMALE; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS, HORMONE-DEPENDENT; PROGNOSIS; RECEPTORS, ANDROGEN;

EID: 84867032762     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2012.08.007     Document Type: Review

References (145)

1. B. Dunn Cancer: solving an age-old problem Nature 483 7387 2012 S2 S6
2. N.R. Bertos, and M. Park Breast cancer - one term, many entities? The Journal of Clinical Investigation 121 10 2011 3789 3796
3. A.R. Razzak, N.U. Lin, and E.P. Winer Heterogeneity of breast cancer and implications of adjuvant chemotherapy Breast Cancer 15 1 2008 31 34
4. M.J. Lund, E.N. Butler, B.Y. Hair, K.C. Ward, J.H. Andrews, G. Oprea-Ilies, A.R. Bayakly, R.M. O'Regan, P.M. Vertino, and J.W. Eley Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes: a population-based study and first report Cancer 116 11 2010 2549 2559
5. L. Schwentner, R. Wolters, K. Koretz, M.B. Wischnewsky, R. Kreienberg, R. Rottscholl, and A. Wockel Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival - a retrospective multi-centre cohort study Breast Cancer Research and Treatment 132 3 2012 1073 1080
6. L.A. Carey Directed therapy of subtypes of triple-negative breast cancer Oncologist 16 Suppl. 1 2011 71 78
7. P. Meijnen, J.L. Peterse, N. Antonini, E.J. Rutgers, and M.J. van de Vijver Immunohistochemical categorisation of ductal carcinoma in situ of the breast British Journal of Cancer 98 1 2008 137 142
8. K. Hanley, J. Wang, P. Bourne, Q. Yang, A.C. Gao, G. Lyman, and P. Tang Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast Human Pathology 39 3 2008 386 392
9. B. Wei, J. Wang, P. Bourne, Q. Yang, D. Hicks, H. Bu, and P. Tang Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas Human Pathology 39 12 2008 1809 1815
10. Y. Ogawa, E. Hai, K. Matsumoto, K. Ikeda, S. Tokunaga, H. Nagahara, K. Sakurai, T. Inoue, and Y. Nishiguchi Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers International Journal of Clinical Oncology 13 5 2008 431 435
11. A.M. Gonzalez-Angulo, K. Stemke-Hale, S.L. Palla, M. Carey, R. Agarwal, F. Meric-Berstam, T.A. Traina, C. Hudis, G.N. Hortobagyi, W.L. Gerald, G.B. Mills, and B.T. Hennessy Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer Clinical Cancer Research 15 7 2009 2472 2478
12. S. Park, J. Koo, H.S. Park, J.H. Kim, S.Y. Choi, J.H. Lee, B.W. Park, and K.S. Lee Expression of androgen receptors in primary breast cancer Annals of Oncology 21 3 2010 488 492
13. L.A. Niemeier, D.J. Dabbs, S. Beriwal, J.M. Striebel, and R. Bhargava Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation Modern Pathology 23 2 2010 205 212
14. X. Luo, Y.X. Shi, Z.M. Li, and W.Q. Jiang Expression and clinical significance of androgen receptor in triple negative breast cancer Chinese Journal of Cancer 29 6 2010 585 590
15. H. Masuda, N. Masuda, Y. Kodama, M. Ogawa, M. Karita, J. Yamamura, K. Tsukuda, H. Doihara, S. Miyoshi, M. Mano, S. Nakamori, and T. Tsujinaka Predictive factors for the effectiveness of neoadjuvant chemotherapy and prognosis in triple-negative breast cancer patients Cancer Chemotherapy and Pharmacology 67 4 2011 911 917
16. M.A. Aleskandarany, E.A. Rakha, M.A. Ahmed, D.G. Powe, I.O. Ellis, and A.R. Green Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer Breast Cancer Research and Treatment 127 2 2011 407 416
17. D. Micello, A. Marando, N. Sahnane, C. Riva, C. Capella, and F. Sessa Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancers Virchows Archiv 457 4 2010 467 476
18. J.S. Koo, W. Jung, and J. Jeong The predictive role of E-cadherin and androgen receptor on in vitro chemosensitivity in triple-negative breast cancer Japanese Journal of Clinical Oncology 39 9 2009 560 568
19. G. Pristauz, E. Petru, E. Stacher, J.B. Geigl, T. Schwarzbraun, O. Tsybrovskyy, R. Winter, and F. Moinfar Androgen receptor expression in breast cancer patients tested for BRCA1 and BRCA2 mutations Histopathology 57 6 2010 877 884
20. J. Chen, X. Zhang, R. Tian, Y. Liu, H.M. Dong, R.F. Guo, and H.Y. Liang Expression of androgen receptor in breast carcinoma and its relationship with estrogen receptor, progesterone receptor and HER2 status Zhonghua Bing Li Xue Za Zhi 39 11 2010 743 746
21. B.J. Chae, A. Lee, J.S. Bae, B.J. Song, and S.S. Jung Expression of nuclear receptor DAX-1 and androgen receptor in human breast cancer Journal of Surgical Oncology 103 8 2011 768 772
22. J. He, R. Peng, Z. Yuan, S. Wang, J. Peng, G. Lin, X. Jiang, and T. Qin Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray Medical Oncology 29 2 2012 406 410
23. S. Park, J.S. Koo, M.S. Kim, H.S. Park, J.S. Lee, S.I. Kim, B.W. Park, and K.S. Lee Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers Annals of Oncology 22 8 2011 1755 1762
24. D. Tang, S. Xu, Q. Zhang, and W. Zhao The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer Medical Oncology 29 2 2012 526 533
25. S. Loibl, B.M. Muller, G. von Minckwitz, M. Schwabe, M. Roller, S. Darb-Esfahani, B. Ataseven, A. du Bois, A. Fissler-Eckhoff, B. Gerber, U. Kulmer, J.U. Alles, K. Mehta, and C. Denkert Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy Breast Cancer Research and Treatment 130 2 2011 477 487
26. J.P. Qi, Y.L. Yang, H. Zhu, J. Wang, Y. Jia, N. Liu, Y.J. Song, L.K. Zan, X. Zhang, M. Zhou, Y.H. Gu, T. Liu, D.G. Hicks, and P. Tang Expression of the androgen receptor and its correlation with molecular subtypes in 980 Chinese breast cancer patients Breast Cancer (Auckl) 6 2012 1 8
27. K. Bauer, C. Parise, and V. Caggiano Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer BMC Cancer 10 2010 228
28. E.K. Kim, W.C. Noh, W. Han, and D.Y. Noh Prognostic significance of young age (<35 years) by subtype based on ER, PR, and HER2 status in breast cancer: a nationwide registry-based study World Journal of Surgery 35 6 2011 1244 1253
29. A.W. Kurian, K. Fish, S.J. Shema, and C.A. Clarke Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups Breast Cancer Research 12 6 2010 R99
30. J.A. Lee, K.I. Kim, J.W. Bae, Y.H. Jung, H. An, and E.S. Lee Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival Breast Cancer Research and Treatment 123 1 2010 177 187
31. C.A. Parise, K.R. Bauer, and V. Caggiano Variation in breast cancer subtypes with age and race/ethnicity Critical Reviews in Oncology/Hematology 76 1 2010 44 52
32. A.I. Phipps, D.S. Buist, K.E. Malone, W.E. Barlow, P.L. Porter, K. Kerlikowske, and C.I. Li Reproductive history and risk of three breast cancer subtypes defined by three biomarkers Cancer Causes & Control 22 3 2011 399 405
33. M.L. Telli, E.T. Chang, A.W. Kurian, T.H. Keegan, L.A. McClure, D. Lichtensztajn, J.M. Ford, and S.L. Gomez Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry Breast Cancer Research and Treatment 127 2 2011 471 478
34. X.R. Yang, J. Chang-Claude, E.L. Goode, F.J. Couch, H. Nevanlinna, R.L. Milne, M. Gaudet, M.K. Schmidt, A. Broeks, A. Cox, P.A. Fasching, R. Hein, A.B. Spurdle, F. Blows, K. Driver, D. Flesch-Janys, J. Heinz, P. Sinn, A. Vrieling, T. Heikkinen, K. Aittomaki, P. Heikkila, C. Blomqvist, J. Lissowska, B. Peplonska, S. Chanock, J. Figueroa, L. Brinton, P. Hall, K. Czene, K. Humphreys, H. Darabi, J. Liu, L.J. Van't Veer, F.E. van Leeuwen, I.L. Andrulis, G. Glendon, J.A. Knight, A.M. Mulligan, F.P. O'Malley, N. Weerasooriya, E.M. John, M.W. Beckmann, A. Hartmann, S.B. Weihbrecht, D.L. Wachter, S.M. Jud, C.R. Loehberg, L. Baglietto, D.R. English, G.G. Giles, C.A. McLean, G. Severi, D. Lambrechts, T. Vandorpe, C. Weltens, R. Paridaens, A. Smeets, P. Neven, H. Wildiers, X. Wang, J.E. Olson, V. Cafourek, Z. Fredericksen, M. Kosel, C. Vachon, H.E. Cramp, D. Connley, S.S. Cross, S.P. Balasubramanian, M.W. Reed, T. Dork, M. Bremer, A. Meyer, J.H. Karstens, A. Ay, T.W. Park-Simon, P. Hillemanns, J.I. Arias Perez, P. Menendez Rodriguez, P. Zamora, J. Benitez, Y.D. Ko, H.P. Fischer, U. Hamann, B. Pesch, T. Bruning, C. Justenhoven, H. Brauch, D.M. Eccles, W.J. Tapper, S.M. Gerty, E.J. Sawyer, I.P. Tomlinson, A. Jones, M. Kerin, N. Miller, N. McInerney, H. Anton-Culver, A. Ziogas, C.Y. Shen, C.N. Hsiung, P.E. Wu, S.L. Yang, J.C. Yu, S.T. Chen, G.C. Hsu, C.A. Haiman, B.E. Henderson, L. Le Marchand, L.N. Kolonel, A. Lindblom, S. Margolin, A. Jakubowska, J. Lubinski, T. Huzarski, T. Byrski, B. Gorski, J. Gronwald, M.J. Hooning, A. Hollestelle, A.M. van den Ouweland, A. Jager, M. Kriege, M.M. Tilanus-Linthorst, M. Collee, S. Wang-Gohrke, K. Pylkas, A. Jukkola-Vuorinen, K. Mononen, M. Grip, P. Hirvikoski, R. Winqvist, A. Mannermaa, V.M. Kosma, J. Kauppinen, V. Kataja, P. Auvinen, Y. Soini, R. Sironen, S.E. Bojesen, D.D. Orsted, D. Kaur-Knudsen, H. Flyger, B.G. Nordestgaard, H. Holland, G. Chenevix-Trench, S. Manoukian, M. Barile, P. Radice, S.E. Hankinson, D.J. Hunter, R. Tamimi, S. Sangrajrang, P. Brennan, J. McKay, F. Odefrey, V. Gaborieau, P. Devilee, P.E. Huijts, R.A. Tollenaar, C. Seynaeve, G.S. Dite, C. Apicella, J.L. Hopper, F. Hammet, H. Tsimiklis, L.D. Smith, M.C. Southey, M.K. Humphreys, D. Easton, P. Pharoah, M.E. Sherman, and M. Garcia-Closas Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies Journal of the National Cancer Institute 103 3 2011 250 263
35. K.R. Bauer, M. Brown, R.D. Cress, C.A. Parise, and V. Caggiano Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry Cancer 109 9 2007 1721 1728
36. C.A. Parise, K.R. Bauer, M.M. Brown, and V. Caggiano Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004 The Breast Journal 15 6 2009 593 602
37. R.G. Kim, E.K. Kim, H.A. Kim, J.S. Koh, M.S. Kim, K.I. Kim, J.I. Lee, N.M. Moon, E. Ko, and W.C. Noh Prognostic significance of molecular subtype in T1N0M0 breast cancer: Korean experience European Journal of Surgical Oncology 37 7 2011 629 634
38. H.C. Kwon, S.Y. Oh, S.H. Kim, S. Lee, K.A. Kwon, Y.J. Choi, G.J. Cho, Y.S. Kim, M. Lee, J.H. Lee, D.C. Kim, H.S. Lee, S.H. Cho, and H.J. Kim Clinical outcomes and breast cancer subtypes in patients with brain metastases Onkologie 33 4 2010 146 152
39. J.S. Koo, and W. Jung Clinicopathlogic and immunohistochemical characteristics of triple negative invasive lobular carcinoma Yonsei Medical Journal 52 1 2011 89 97
40. A. Stark, C.G. Kleer, I. Martin, B. Awuah, A. Nsiah-Asare, V. Takyi, M. Braman, S.E. Quayson, R. Zarbo, M. Wicha, and L. Newman African ancestry and higher prevalence of triple-negative breast cancer: findings from an international study Cancer 116 21 2010 4926 4932
41. M.L. Kwan, L.H. Kushi, E. Weltzien, B. Maring, S.E. Kutner, R.S. Fulton, M.M. Lee, C.B. Ambrosone, and B.J. Caan Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors Breast Cancer Research 11 3 2009 R31
42. K.F. Trivers, M.J. Lund, P.L. Porter, J.M. Liff, E.W. Flagg, R.J. Coates, and J.W. Eley The epidemiology of triple-negative breast cancer, including race Cancer Causes & Control 20 7 2009 1071 1082
43. M.J. Lund, K.F. Trivers, P.L. Porter, R.J. Coates, B. Leyland-Jones, O.W. Brawley, E.W. Flagg, R.M. O'Regan, S.G. Gabram, and J.W. Eley Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA Breast Cancer Research and Treatment 113 2 2009 357 370
44. D. Huo, F. Ikpatt, A. Khramtsov, J.M. Dangou, R. Nanda, J. Dignam, B. Zhang, T. Grushko, C. Zhang, O. Oluwasola, D. Malaka, S. Malami, A. Odetunde, A.O. Adeoye, F. Iyare, A. Falusi, C.M. Perou, and O.I. Olopade Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer Journal of Clinical Oncology 27 27 2009 4515 4521
45. M.A. Aleskandarany, E.A. Rakha, M.A. Ahmed, D.G. Powe, E.C. Paish, R.D. Macmillan, I.O. Ellis, and A.R. Green PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis Breast Cancer Research and Treatment 122 1 2010 45 53
46. S. Woditschka, L.A. Habel, N. Udaltsova, G.D. Friedman, and W. Sieh Lipophilic statin use and risk of breast cancer subtypes Cancer Epidemiology, Biomarkers & Prevention 19 10 2010 2479 2487
47. L.A. Carey, E.C. Dees, L. Sawyer, L. Gatti, D.T. Moore, F. Collichio, D.W. Ollila, C.I. Sartor, M.L. Graham, and C.M. Perou The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes Clinical Cancer Research 13 8 2007 2329 2334
48. R. Dent, W.M. Hanna, M. Trudeau, E. Rawlinson, P. Sun, and S.A. Narod Pattern of metastatic spread in triple-negative breast cancer Breast Cancer Research and Treatment 115 2 2009 423 428
49. F. Heitz, P. Harter, H.J. Lueck, A. Fissler-Eckhoff, F. Lorenz-Salehi, S. Scheil-Bertram, A. Traut, and A. du Bois Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases European Journal of Cancer 45 16 2009 2792 2798
50. E.A. Rakha, S.E. Elsheikh, M.A. Aleskandarany, H.O. Habashi, A.R. Green, D.G. Powe, M.E. El-Sayed, A. Benhasouna, J.S. Brunet, L.A. Akslen, A.J. Evans, R. Blamey, J.S. Reis-Filho, W.D. Foulkes, and I.O. Ellis Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes Clinical Cancer Research 15 7 2009 2302 2310
51. D. Trere, E. Brighenti, G. Donati, C. Ceccarelli, D. Santini, M. Taffurelli, L. Montanaro, and M. Derenzini High prevalence of retinoblastoma protein loss in triple-negative breast cancers and its association with a good prognosis in patients treated with adjuvant chemotherapy Annals of Oncology 20 11 2009 1818 1823
52. J. Hugh, J. Hanson, M.C. Cheang, T.O. Nielsen, C.M. Perou, C. Dumontet, J. Reed, M. Krajewska, I. Treilleux, M. Rupin, E. Magherini, J. Mackey, M. Martin, and C. Vogel Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial Journal of Clinical Oncology 27 8 2009 1168 1176
53. S. Nofech-Mozes, M. Trudeau, H.K. Kahn, R. Dent, E. Rawlinson, P. Sun, S.A. Narod, and W.M. Hanna Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers Breast Cancer Research and Treatment 118 1 2009 131 137
54. T. Islam, K. Matsuo, H. Ito, S. Hosono, M. Watanabe, H. Iwata, K. Tajima, and H. Tanaka Reproductive and hormonal risk factors for luminal, HER2-overexpressing, and triple-negative breast cancer in Japanese women Annals of Oncology 23 9 2012 2435 2441
55. Y. Ishikawa, J. Horiguchi, H. Toya, H. Nakajima, M. Hayashi, N. Tagaya, I. Takeyoshi, and T. Oyama Triple-negative breast cancer: histological subtypes and immunohistochemical and clinicopathological features Cancer Science 102 3 2011 656 662
56. H. Nogi, T. Kobayashi, M. Suzuki, I. Tabei, K. Kawase, Y. Toriumi, H. Fukushima, and K. Uchida EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer Oncology Reports 21 2 2009 413 417
57. M. Sasa, Y. Bando, M. Takahashi, T. Hirose, and T. Nagao Screening for basal marker expression is necessary for decision of therapeutic strategy for triple-negative breast cancer Journal of Surgical Oncology 97 1 2008 30 34
58. C.R. Devi, T.S. Tang, and M. Corbex Incidence and risk factors for breast cancer subtypes in three distinct South-East Asian ethnic groups: Chinese, Malay and natives of Sarawak, Malaysia International Journal of Cancer 2012 10.1002/ijc.27527
59. X.S. Chen, J.Y. Wu, O. Huang, C.M. Chen, J. Wu, J.S. Lu, Z.M. Shao, Z.Z. Shen, and K.W. Shen Molecular subtype can predict the response and outcome of Chinese locally advanced breast cancer patients treated with preoperative therapy Oncology Reports 23 5 2010 1213 1220
60. Y. Lin, W. Yin, T. Yan, L. Zhou, G. Di, J. Wu, Z. Shen, Z. Shao, and J. Lu Site-specific relapse pattern of the triple negative tumors in Chinese breast cancer patients BMC Cancer 9 2009 342
61. H. Liu, Q.H. Fan, Z.H. Zhang, X. Li, H.P. Yu, G.Z. Liu, and F.Q. Meng Roles of immunohistochemistry in prognostic assessment of basal-like breast cancer Zhonghua Bing Li Xue Za Zhi 38 1 2009 23 28
62. Y. Su, Y. Zheng, W. Zheng, K. Gu, Z. Chen, G. Li, Q. Cai, W. Lu, and X.O. Shu Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study BMC Cancer 11 2011 292
63. P. Xing, J. Li, and F. Jin A case-control study of reproductive factors associated with subtypes of breast cancer in Northeast China Medical Oncology 27 3 2010 926 931
64. E. Lee, R. McKean-Cowdin, H. Ma, D.V. Spicer, D. Van Den Berg, L. Bernstein, and G. Ursin Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women Journal of Clinical Oncology 29 33 2011 4373 4380
65. E. Comen, M. Davids, T. Kirchhoff, C. Hudis, K. Offit, and M. Robson Relative contributions of BRCA1 and BRCA2 mutations to "triple- negative" breast cancer in Ashkenazi Women Breast Cancer Research and Treatment 129 1 2011 185 190
66. J. Zidan, N. Sikorsky, W. Basher, A. Sharabi, E. Friedman, and M. Steiner Differences in pathological and clinical features of breast cancer in Arab as compared to Jewish women in Northern Israel International Journal of Cancer 131 4 2012 924 929
67. J.M. Dolle, J.R. Daling, E. White, L.A. Brinton, D.R. Doody, P.L. Porter, and K.E. Malone Risk factors for triple-negative breast cancer in women under the age of 45 years Cancer Epidemiology, Biomarkers & Prevention 18 4 2009 1157 1166
68. N.U. Lin, A. Vanderplas, M.E. Hughes, R.L. Theriault, S.B. Edge, Y.N. Wong, D.W. Blayney, J.C. Niland, E.P. Winer, and J.C. Weeks Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network Cancer 2012 10.1002/cncr.27581
69. A.I. Phipps, R.T. Chlebowski, R. Prentice, A. McTiernan, J. Wactawski-Wende, L.H. Kuller, L.L. Adams-Campbell, D. Lane, M.L. Stefanick, M. Vitolins, G.C. Kabat, T.E. Rohan, and C.I. Li Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer Journal of the National Cancer Institute 103 6 2011 470 477
70. R.T. Falk, E. Gentzschein, F.Z. Stanczyk, M. Garcia-Closas, J.D. Figueroa, O.B. Ioffe, J. Lissowska, L.A. Brinton, and M.E. Sherman Sex steroid hormone levels in breast adipose tissue and serum in postmenopausal women Breast Cancer Research and Treatment 131 1 2012 287 294
71. Y. Kakugawa, Y. Minami, H. Tateno, H. Inoue, and T. Fujiya Relation of serum levels of estrogen and dehydroepiandrosterone sulfate to hormone receptor status among postmenopausal women with breast cancer Breast Cancer 14 3 2007 269 276
72. R.E. James, A. Lukanova, L. Dossus, S. Becker, S. Rinaldi, A. Tjonneland, A. Olsen, K. Overvad, S. Mesrine, P. Engel, F. Clavel-Chapelon, J. Chang-Claude, A. Vrieling, H. Boeing, M. Schutze, A. Trichopoulou, P. Lagiou, D. Trichopoulos, D. Palli, V. Krogh, S. Panico, R. Tumino, C. Sacerdote, L. Rodriguez, G. Buckland, M.J. Sanchez, P. Amiano, E. Ardanaz, B. Bueno-de-Mesquita, M.M. Ros, C.H. van Gils, P.H. Peeters, K.T. Khaw, N. Wareham, T.J. Key, N.E. Allen, I. Romieu, A. Siddiq, D. Cox, E. Riboli, and R. Kaaks Postmenopausal serum sex steroids and risk of hormone receptor-positive and -negative breast cancer: a nested case-control study Cancer Prevention Research (Phila) 4 10 2011 1626 1635
73. G.N. Farhat, S.R. Cummings, R.T. Chlebowski, N. Parimi, J.A. Cauley, T.E. Rohan, A.J. Huang, M. Vitolins, F.A. Hubbell, J.E. Manson, B.B. Cochrane, D.S. Lane, and J.S. Lee Sex hormone levels and risks of estrogen receptor-negative and estrogen receptor-positive breast cancers Journal of the National Cancer Institute 103 7 2011 562 570
74. S. Sieri, V. Krogh, G. Bolelli, C.A. Abagnato, S. Grioni, V. Pala, A. Evangelista, C. Allemani, A. Micheli, G. Tagliabue, H.J. Schunemann, S. Menard, F. Berrino, and P. Muti Sex hormone levels, breast cancer risk, and cancer receptor status in postmenopausal women: the ORDET cohort Cancer Epidemiology, Biomarkers & Prevention 18 1 2009 169 176
75. S. Irshad, P. Ellis, and A. Tutt Molecular heterogeneity of triple-negative breast cancer and its clinical implications Current Opinion in Oncology 23 6 2011 566 577
76. C.M. Perou Molecular stratification of triple-negative breast cancers Oncologist 16 Suppl. 1 2011 61 70
77. V.J. Weigman, H.H. Chao, A.A. Shabalin, X. He, J.S. Parker, S.H. Nordgard, T. Grushko, D. Huo, C. Nwachukwu, A. Nobel, V.N. Kristensen, A.L. Borresen-Dale, O.I. Olopade, and C.M. Perou Basal-like breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival Breast Cancer Research and Treatment 133 3 2012 865 880
78. G. Peiro, E. Adrover, L. Sanchez-Tejada, E. Lerma, M. Planelles, J. Sanchez-Paya, F.I. Aranda, D. Giner, and F.J. Gutierrez-Avino Increased insulin-like growth factor-1 receptor mRNA expression predicts poor survival in immunophenotypes of early breast carcinoma Modern Pathology 24 2 2011 201 208
79. K. Rennstam, N. McMichael, P. Berglund, G. Honeth, C. Hegardt, L. Ryden, L. Luts, P.O. Bendahl, and I. Hedenfalk Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer Breast Cancer Research and Treatment 122 2 2010 315 324
80. M. Smid, M. Hoes, A.M. Sieuwerts, S. Sleijfer, Y. Zhang, Y. Wang, J.A. Foekens, and J.W. Martens Patterns and incidence of chromosomal instability and their prognostic relevance in breast cancer subtypes Breast Cancer Research and Treatment 128 1 2011 23 30
81. K.D. Voduc, M.C. Cheang, S. Tyldesley, K. Gelmon, T.O. Nielsen, and H. Kennecke Breast cancer subtypes and the risk of local and regional relapse Journal of Clinical Oncology 28 10 2010 1684 1691
82. M.M. Gaudet, M.F. Press, R.W. Haile, C.F. Lynch, S.L. Glaser, J. Schildkraut, M.D. Gammon, W. Douglas Thompson, and J.L. Bernstein Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger Breast Cancer Research and Treatment 130 2 2011 587 597
83. J.M. Olefsky Nuclear receptor minireview series The Journal of Biological Chemistry 276 40 2001 36863 36864
84. A.O. Brinkmann Molecular mechanisms of androgen action - a historical perspective Methods in Molecular Biology 776 2011 3 24
85. C.J. Ryan, and D.J. Tindall Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically Journal of Clinical Oncology 29 27 2011 3651 3658
86. M.E. Lippman, G. Bolan, and K. Huff Human breast cancer responsive to androgen in long term tissue culture Nature 258 5533 1975 339 341
87. H. Flax, H. Salih, K.A. Newton, and J.R. Hobbs Are some women's breast cancers androgen dependent? Lancet 1 7814 1973 1204 1207
88. M.M. Brentani, E.L. Franco, C.T. Oshima, and M.M. Pacheco Androgen, estrogen, and progesterone receptor levels in malignant and benign breast tumors: a multivariate analysis approach International Journal of Cancer 38 5 1986 637 642
89. J.A. Soreide, O.A. Lea, J.E. Varhaug, A. Skarstein, and S. Kvinnsland Androgen receptors in operable breast cancer: relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment European Journal of Surgical Oncology 18 2 1992 112 118
90. S.N. Birrell, J.M. Bentel, T.E. Hickey, C. Ricciardelli, M.A. Weger, D.J. Horsfall, and W.D. Tilley Androgens induce divergent proliferative responses in human breast cancer cell lines The Journal of Steroid Biochemistry and Molecular Biology 52 5 1995 459 467
91. R.E. Hall, J.A. Clements, S.N. Birrell, and W.D. Tilley Prostate-specific antigen and gross cystic disease fluid protein-15 are co-expressed in androgen receptor-positive breast tumours British Journal of Cancer 78 3 1998 360 365
92. R.E. Hall, J.O. Aspinall, D.J. Horsfall, S.N. Birrell, J.M. Bentel, R.L. Sutherland, and W.D. Tilley Expression of the androgen receptor and an androgen-responsive protein, apolipoprotein D, in human breast cancer British Journal of Cancer 74 8 1996 1175 1180
93. F. Moinfar, M. Okcu, O. Tsybrovskyy, P. Regitnig, S.F. Lax, W. Weybora, M. Ratschek, F.A. Tavassoli, and H. Denk Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies Cancer 98 4 2003 703 711
94. J.J. Isola Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors The Journal of Pathology 170 1 1993 31 35
95. V. Kuenen-Boumeester, T.H. Van der Kwast, W.L. van Putten, C. Claassen, B. van Ooijen, and S.C. Henzen-Logmans Immunohistochemical determination of androgen receptors in relation to oestrogen and progesterone receptors in female breast cancer International Journal of Cancer 52 4 1992 581 584
96. O.A. Lea, S. Kvinnsland, and T. Thorsen Improved measurement of androgen receptors in human breast cancer Cancer Research 49 24 Pt 1 1989 7162 7167
97. R. Hu, S. Dawood, M.D. Holmes, L.C. Collins, S.J. Schnitt, K. Cole, J.D. Marotti, S.E. Hankinson, G.A. Colditz, and R.M. Tamimi Androgen receptor expression and breast cancer survival in postmenopausal women Clinical Cancer Research 17 7 2011 1867 1874
98. U. Simanainen, Y.R. Gao, K.A. Walters, G. Watson, R. Desai, M. Jimenez, and D.J. Handelsman Androgen resistance in female mice increases susceptibility to DMBA-induced mammary tumors Hormones and Cancer 3 3 2012 113 124
99. A.A. Peters, W.V. Ingman, W.D. Tilley, and L.M. Butler Differential effects of exogenous androgen and an androgen receptor antagonist in the peri- and postpubertal murine mammary gland Endocrinology 152 10 2011 3728 3737
100. I. Castellano, E. Allia, V. Accortanzo, A.M. Vandone, L. Chiusa, R. Arisio, A. Durando, M. Donadio, G. Bussolati, A.S. Coates, G. Viale, and A. Sapino Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers Breast Cancer Research and Treatment 124 3 2010 607 617
101. L.O. Gonzalez, M.D. Corte, J. Vazquez, S. Junquera, R. Sanchez, A.C. Alvarez, J.C. Rodriguez, M.L. Lamelas, and F.J. Vizoso Androgen receptor expression in breast cancer: relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors BMC Cancer 8 2008 149
102. A.A. Peters, G. Buchanan, C. Ricciardelli, T. Bianco-Miotto, M.M. Centenera, J.M. Harris, S. Jindal, D. Segara, L. Jia, N.L. Moore, S.M. Henshall, S.N. Birrell, G.A. Coetzee, R.L. Sutherland, L.M. Butler, and W.D. Tilley Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer Cancer Research 69 15 2009 6131 6140
103. H. Soiland, H. Korner, I. Skaland, E.A. Janssen, E. Gudlaugsson, J.E. Varhaug, J.P. Baak, and J.A. Soreide Prognostic relevance of androgen receptor detection in operable breast cancer Journal of Surgical Oncology 98 7 2008 551 558
104. A. Naderi, K.M. Chia, and J. Liu Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer Breast Cancer Research 13 2 2011 R36
105. J.L. Robinson, S. MacArthur, C.S. Ross-Innes, W.D. Tilley, D.E. Neal, I.G. Mills, and J.S. Carroll Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1 The EMBO Journal 30 15 2011 3019 3027
106. T. Suzuki, Y. Miki, K. Takagi, H. Hirakawa, T. Moriya, N. Ohuchi, and H. Sasano Androgens in human breast carcinoma Medical Molecular Morphology 43 2 2010 75 81
107. Y. Tsutsumi Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma Japanese Journal of Clinical Oncology 42 5 2012 375 386
108. J. Kao, K. Salari, M. Bocanegra, Y.L. Choi, L. Girard, J. Gandhi, K.A. Kwei, T. Hernandez-Boussard, P. Wang, A.F. Gazdar, J.D. Minna, and J.R. Pollack Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery PLoS One 4 7 2009 e6146
109. B.D. Lehmann, J.A. Bauer, X. Chen, M.E. Sanders, A.B. Chakravarthy, Y. Shyr, and J.A. Pietenpol Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies The Journal of Clinical Investigation 121 7 2011 2750 2767
110. A. Hollestelle, J.H. Nagel, M. Smid, S. Lam, F. Elstrodt, M. Wasielewski, S.S. Ng, P.J. French, J.K. Peeters, M.J. Rozendaal, M. Riaz, D.G. Koopman, T.L. Ten Hagen, B.H. de Leeuw, E.C. Zwarthoff, A. Teunisse, P.J. van der Spek, J.G. Klijn, W.N. Dinjens, S.P. Ethier, H. Clevers, A.G. Jochemsen, M.A. den Bakker, J.A. Foekens, J.W. Martens, and M. Schutte Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines Breast Cancer Research and Treatment 121 1 2010 53 64
111. R.M. Neve, K. Chin, J. Fridlyand, J. Yeh, F.L. Baehner, T. Fevr, L. Clark, N. Bayani, J.P. Coppe, F. Tong, T. Speed, P.T. Spellman, S. DeVries, A. Lapuk, N.J. Wang, W.L. Kuo, J.L. Stilwell, D. Pinkel, D.G. Albertson, F.M. Waldman, F. McCormick, R.B. Dickson, M.D. Johnson, M. Lippman, S. Ethier, A. Gazdar, and J.W. Gray A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes Cancer Cell 10 6 2006 515 527
112. C.M. Perou, T. Sorlie, M.B. Eisen, M. van de Rijn, S.S. Jeffrey, C.A. Rees, J.R. Pollack, D.T. Ross, H. Johnsen, L.A. Akslen, O. Fluge, A. Pergamenschikov, C. Williams, S.X. Zhu, P.E. Lonning, A.L. Borresen-Dale, P.O. Brown, and D. Botstein Molecular portraits of human breast tumours Nature 406 6797 2000 747 752
113. R.E. Hall, S.N. Birrell, W.D. Tilley, and R.L. Sutherland MDA-MB-453, an androgen-responsive human breast carcinoma cell line with high level androgen receptor expression European Journal of Cancer 30A 4 1994 484 490
114. D.L. Holliday, and V. Speirs Choosing the right cell line for breast cancer research Breast Cancer Research 13 4 2011 215
115. S. Vranic, Z. Gatalica, and Z.Y. Wang Update on the molecular profile of the MDA-MB-453 cell line as a model for apocrine breast carcinoma studies Oncology Letters 2 6 2011 1131 1137
116. A. Capes-Davis, G. Theodosopoulos, I. Atkin, H.G. Drexler, A. Kohara, R.A. MacLeod, J.R. Masters, Y. Nakamura, Y.A. Reid, R.R. Reddel, and R.I. Freshney Check your cultures! A list of cross-contaminated or misidentified cell lines International Journal of Cancer 127 1 2010 1 8
117. N.L. Moore, G. Buchanan, J. Harris, L.A. Selth, T. Bianco-Miotto, A.R. Hanson, S. Birrell, L.M. Butler, T. Hickey, and W.D. Tilley An androgen receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activity Endocrine-Related Cancer 19 4 2012 599 613
118. A. Magklara, T.J. Brown, and E.P. Diamandis Characterization of androgen receptor and nuclear receptor co-regulator expression in human breast cancer cell lines exhibiting differential regulation of kallikreins 2 and 3 International Journal of Cancer 100 5 2002 507 514
119. C. Hardin, R. Pommier, K. Calhoun, P. Muller, T. Jackson, and S. Pommier A new hormonal therapy for estrogen receptor-negative breast cancer World Journal of Surgery 31 5 2007 1041 1046
120. K. Subik, J.F. Lee, L. Baxter, T. Strzepek, D. Costello, P. Crowley, L. Xing, M.C. Hung, T. Bonfiglio, D.G. Hicks, and P. Tang The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by immunohistochemical analysis in breast cancer cell lines Breast Cancer (Auckl) 4 2010 35 41
121. T.R. Graham, R. Yacoub, L. Taliaferro-Smith, A.O. Osunkoya, V.A. Odero-Marah, T. Liu, K.S. Kimbro, D. Sharma, and R.M. O'Regan Reciprocal regulation of ZEB1 and AR in triple negative breast cancer cells Breast Cancer Research and Treatment 123 1 2010 139 147
122. K.A. Link, C.J. Burd, E. Williams, T. Marshall, G. Rosson, E. Henry, B. Weissman, and K.E. Knudsen BAF57 governs androgen receptor action and androgen-dependent proliferation through SWI/SNF Molecular and Cellular Biology 25 6 2005 2200 2215
123. J. Malone, and R. Ullrich Novel radiation response genes identified in gene-trapped MCF10A mammary epithelial cells Radiation Research 167 2 2007 176 184
124. A.S. Doane, M. Danso, P. Lal, M. Donaton, L. Zhang, C. Hudis, and W.L. Gerald An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen Oncogene 25 28 2006 3994 4008
125. P. Farmer, H. Bonnefoi, V. Becette, M. Tubiana-Hulin, P. Fumoleau, D. Larsimont, G. Macgrogan, J. Bergh, D. Cameron, D. Goldstein, S. Duss, A.L. Nicoulaz, C. Brisken, M. Fiche, M. Delorenzi, and R. Iggo Identification of molecular apocrine breast tumours by microarray analysis Oncogene 24 29 2005 4660 4671
126. C.J. Ormandy, C.L. Clarke, P.A. Kelly, and R.L. Sutherland Androgen regulation of prolactin-receptor gene expression in MCF-7 and MDA-MB-453 human breast cancer cells International Journal of Cancer 50 5 1992 777 782
127. R.E. Hall, W.D. Tilley, M.J. McPhaul, and R.L. Sutherland Regulation of androgen receptor gene expression by steroids and retinoic acid in human breast-cancer cells International Journal of Cancer 52 5 1992 778 784
128. J.M. Bentel, S.N. Birrell, M.A. Pickering, D.J. Holds, D.J. Horsfall, and W.D. Tilley Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells Molecular and Cellular Endocrinology 154 1-2 1999 11 20
129. S. Mitchell, P. Abel, S. Madaan, J. Jeffs, K. Chaudhary, G. Stamp, and N. Lalani el Androgen-dependent regulation of human MUC1 mucin expression Neoplasia 4 1 2002 9 18
130. M. Ni, Y. Chen, E. Lim, H. Wimberly, S.T. Bailey, Y. Imai, D.L. Rimm, X.S. Liu, and M. Brown Targeting androgen receptor in estrogen receptor-negative breast cancer Cancer Cell 20 1 2011 119 131
131. R. Hackenberg, S. Luttchens, J. Hofmann, R. Kunzmann, F. Holzel, and K.D. Schulz Androgen sensitivity of the new human breast cancer cell line MFM-223 Cancer Research 51 20 1991 5722 5727
132. R. Hackenberg, T. Hawighorst, A. Filmer, A.H. Nia, and K.D. Schulz Medroxyprogesterone acetate inhibits the proliferation of estrogen- and progesterone-receptor negative MFM-223 human mammary cancer cells via the androgen receptor Breast Cancer Research and Treatment 25 3 1993 217 224
133. R. Hackenberg, T. Hawighorst, A. Filmer, E.P. Slater, K. Bock, M. Beato, and K.D. Schulz Regulation of androgen receptor mRNA and protein level by steroid hormones in human mammary cancer cells The Journal of Steroid Biochemistry and Molecular Biology 43 7 1992 599 607
134. J.P. Garay, B. Karakas, A.M. Abukhdeir, D.P. Cosgrove, J.P. Gustin, M.J. Higgins, H. Konishi, Y. Konishi, J. Lauring, M. Mohseni, G.M. Wang, D. Jelovac, A. Weeraratna, C.A. Sherman Baust, P.J. Morin, A. Toubaji, A. Meeker, A.M. De Marzo, G. Lewis, A. Subhawong, P. Argani, and B.H. Park The growth response to androgen receptor signaling in ERalpha-negative human breast cells is dependent on p21 and mediated by MAPK activation Breast Cancer Research 14 1 2012 R27
135. T.K. Kim, and J.H. Eberwine Mammalian cell transfection: the present and the future Analytical and Bioanalytical Chemistry 397 8 2010 3173 3178
136. M.L. Garcia-Hernandez, R. Hernandez-Pando, P. Gariglio, and J. Berumen Interleukin-10 promotes B16-melanoma growth by inhibition of macrophage functions and induction of tumour and vascular cell proliferation Immunology 105 2 2002 231 243
137. E.F. Brandon, C.D. Raap, I. Meijerman, J.H. Beijnen, and J.H. Schellens An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons Toxicology and Applied Pharmacology 189 3 2003 233 246
138. S.N. Agoff, P.E. Swanson, H. Linden, S.E. Hawes, and T.J. Lawton Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations American Journal of Clinical Pathology 120 5 2003 725 731
139. E.A. Rakha, M.E. El-Sayed, A.R. Green, A.H. Lee, J.F. Robertson, and I.O. Ellis Prognostic markers in triple-negative breast cancer Cancer 109 1 2007 25 32
140. A. Gucalp, and T.A. Traina Triple-negative breast cancer: role of the androgen receptor Cancer Journal 16 1 2010 62 65
141. T. Suzuki, Y. Miki, T. Moriya, J. Akahira, T. Ishida, H. Hirakawa, Y. Yamaguchi, S. Hayashi, and H. Sasano 5α-Reductase type 1 and aromatase in breast carcinoma as regulators of in situ androgen production International Journal of Cancer 120 2 2007 285 291
142. R. Shibuya, T. Suzuki, Y. Miki, K. Yoshida, T. Moriya, K. Ono, J. Akahira, T. Ishida, H. Hirakawa, D.B. Evans, and H. Sasano Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast Endocrine-Related Cancer 15 1 2008 113 124
143. A.M. Moorman, R. Vink, H.J. Heijmans, J. van der Palen, and E.A. Kouwenhoven The prognostic value of tumour-stroma ratio in triple-negative breast cancer European Journal of Surgical Oncology 38 4 2012 307 313
144. E.M. de Kruijf, J.G. van Nes, C.J. van de Velde, H. Putter, V.T. Smit, G.J. Liefers, P.J. Kuppen, R.A. Tollenaar, and W.E. Mesker Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients Breast Cancer Research and Treatment 125 3 2011 687 696
145. A.K. Witkiewicz, D. Whitaker-Menezes, A. Dasgupta, N.J. Philp, Z. Lin, R. Gandara, S. Sneddon, U.E. Martinez-Outschoorn, F. Sotgia, and M.P. Lisanti Using the "reverse Warburg effect" to identify high-risk breast cancer patients: stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers Cell Cycle 11 6 2012 1108 1117